DEA
EW icon

DoubleLine ETF Adviser’s Edwards Lifesciences EW Stock Holding History

DoubleLine ETF Adviser’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$576K Sell
6,365
-757
-11% -$63.4K 0.24% 106
2026
Q1 		$570K Buy
+7,122
New +$587K 0.22% 107

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

DoubleLine ETF Adviser's EW Position: Q2 2026 in Review

DoubleLine ETF Adviser reduced its Edwards Lifesciences (EW) stake by 11% in Q2 2026, selling an estimated $63.4K and leaving 6,365 shares worth $576K. The position accounts for 0.24% of the portfolio, ranked #106.

DoubleLine ETF Adviser first reported a position in EW in Q1 2026 and has held it in 2 quarters since. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • DoubleLine ETF Adviser held 6,365 shares of Edwards Lifesciences worth $576K as of Q2 2026.
  • DoubleLine ETF Adviser sold 757 Edwards Lifesciences shares in Q2 2026, an estimated $63.4K.
  • Edwards Lifesciences made up 0.24% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #106 holding.
  • DoubleLine ETF Adviser first reported a position in Edwards Lifesciences in Q1 2026 and has held it in 2 quarters since.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.